arrow
É

Édith Borcoman

Institut Curie
H指数:24
被引数:2,547

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer

非小细胞肺癌中滤泡CD4+T细胞在淋巴结和肿瘤间的克隆共享与可塑性

2026-08-200
OA
SCANDARE: an institutional dynamic prospective interventional biobanking study

SCANDARE:一项机构动态前瞻性干预生物银行研究

2026-02-050
OAAI
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

帕博利珠单抗和伏立诺他联合治疗复发性/转移性鳞状细胞癌的疗效:一项II期篮式试验

2025-06-300
OAAI
CD8+ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance

乳腺癌肿瘤和引流淋巴结中CD8+ T细胞:PD-1水平、效应功能及预后相关性

2025-05-120
OAAI
Durvalumab and tremelimumab in combination with metronomic oral vinorelbine for recurrent advanced cervical cancer: an open-label phase I/II study

度伐利尤单抗和特瑞普利单抗与常规口服长春瑞滨联合治疗复发性晚期宫颈癌:一项开放标签的I/II期研究

2025-01-071
OA
CD74 supports accumulation and function of regulatory T cells in tumors
2024-05-034
OAAI
CSFctDNA as a surrogate for tumor tissue DNA in BC pts with CNS metastases: First results from the Brainstorm program (Oncodistinct 006)
2024-04-050
PRE
EGL-001 is a novel immunocytokine designed to specifically target and disarm T regulatory cells in the tumor microenvironment
2024-03-220
PRE
Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity
2023-12-182
OAAI
Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board
2023-12-010
PRE
BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors
2023-10-190
PRE
Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers
2023-09-016
PRE
CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade

具有耗竭特性和细胞毒性潜能的CD39常规CD4 T细胞浸润肿瘤并在CTLA-4阻断后扩展

2023-08-186
OA
Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinoma
2022-05-1015
OA
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer
2021-11-1117
OAAI
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial
2021-11-0145
PREAI